QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. More Details
Mediocre balance sheet and overvalued.
Share Price & News
How has QIAGEN's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QGEN has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: QGEN exceeded the US Life Sciences industry which returned 46.7% over the past year.
Return vs Market: QGEN exceeded the US Market which returned 18.5% over the past year.
Price Volatility Vs. Market
How volatile is QIAGEN's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StUpdate: QIAGEN (NYSE:QGEN) Stock Gained 43% In The Last Five Years
8 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of QIAGEN N.V. (NYSE:QGEN)?
9 months ago | Simply Wall StWe Think QIAGEN (NYSE:QGEN) Is Taking Some Risk With Its Debt
Is QIAGEN undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: QGEN ($50.58) is trading above our estimate of fair value ($27.31)
Significantly Below Fair Value: QGEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QGEN is poor value based on its PE Ratio (675x) compared to the US Life Sciences industry average (44.8x).
PE vs Market: QGEN is poor value based on its PE Ratio (675x) compared to the US market (19x).
Price to Earnings Growth Ratio
PEG Ratio: QGEN is poor value based on its PEG Ratio (48.2x)
Price to Book Ratio
PB vs Industry: QGEN is good value based on its PB Ratio (4.8x) compared to the US Life Sciences industry average (6.9x).
How is QIAGEN forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QGEN's forecast earnings growth (14% per year) is above the savings rate (2.2%).
Earnings vs Market: QGEN's earnings (14% per year) are forecast to grow slower than the US market (22.2% per year).
High Growth Earnings: QGEN's earnings are forecast to grow, but not significantly.
Revenue vs Market: QGEN's revenue (5.1% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: QGEN's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (11.6%).
How has QIAGEN performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QGEN has a large one-off loss of $315.3M impacting its June 30 2020 financial results.
Growing Profit Margin: QGEN's current net profit margins (1.1%) are lower than last year (11.2%).
Past Earnings Growth Analysis
Earnings Trend: QGEN's earnings have declined by 20% per year over the past 5 years.
Accelerating Growth: QGEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: QGEN had negative earnings growth (-90%) over the past year, making it difficult to compare to the Life Sciences industry average (14.9%).
Return on Equity
High ROE: QGEN's Return on Equity (0.7%) is considered low.
How is QIAGEN's financial position?
Financial Position Analysis
Short Term Liabilities: QGEN's short term assets ($1.6B) exceed its short term liabilities ($959.7M).
Long Term Liabilities: QGEN's short term assets ($1.6B) do not cover its long term liabilities ($2.0B).
Debt to Equity History and Analysis
Debt Level: QGEN's debt to equity ratio (68.3%) is considered high.
Reducing Debt: QGEN's debt to equity ratio has increased from 41.3% to 68.3% over the past 5 years.
Debt Coverage: QGEN's debt is well covered by operating cash flow (21.2%).
Interest Coverage: QGEN's interest payments on its debt are well covered by EBIT (6.6x coverage).
What is QIAGEN current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thierry Bernard (55 yo)
Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and had been its Interim Chief Executive Officer since October 2019 until March 2020. He has been a Director at T2 Biosy ...
CEO Compensation Analysis
Compensation vs Market: Thierry's total compensation ($USD1.21M) is below average for companies of similar size in the US market ($USD11.20M).
Compensation vs Earnings: Insufficient data to compare Thierry's compensation with company performance.
|Chief Executive Officer||1yr||US$1.21m||0.022% |
|CFO, MD & Member of Management Board||16.75yrs||US$925.00k||0.074% |
|Senior Advisor||1yr||US$7.55m||no data|
|Senior VP & Head of Global Operations||1.83yrs||no data||no data|
|Vice President of Corporate Communications & Investor Relations||10yrs||no data||no data|
|Head of Corporate Business Development||5.42yrs||no data||no data|
|SVP & Head of Human Resources||1yr||no data||no data|
|Senior Vice President of Life Science Business Area||2.75yrs||no data||no data|
|Senior Vice President of Qiagen Digital Insights Business Area||2.75yrs||no data||no data|
|Vice President of Global Treasury||no data||no data||no data|
|Associate Director of Investor Relations||no data||no data||no data|
|Senior Advisor to the Chief Executive Officer||5.42yrs||no data||no data|
Experienced Management: QGEN's management team is considered experienced (2.8 years average tenure).
|Independent Supervisory Director||16.75yrs||US$75.50k||1.55% |
|Independent Supervisory Director||9.33yrs||US$96.50k||0.013% |
|Independent Chairman of Supervisory Board||0.17yr||US$82.50k||no data|
|Independent Supervisory Director||6.33yrs||US$63.50k||0% |
|Independent Supervisory Director||7.33yrs||US$89.50k||0.0070% |
|Independent Supervisory Director||4.75yrs||US$63.50k||0.00094% |
Experienced Board: QGEN's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
QIAGEN N.V.'s company bio, employee growth, exchange listings and data sources
- Name: QIAGEN N.V.
- Ticker: QGEN
- Exchange: NYSE
- Founded: 1986
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$11.570b
- Shares outstanding: 228.74m
- Website: https://www.qiagen.com
Number of Employees
- QIAGEN N.V.
- Hulsterweg 82
- 5912 PL
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|QGEN||NYSE (New York Stock Exchange)||Yes||Common Shares||US||USD||Jun 1996|
|QIA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 1996|
|QIA||XTRA (XETRA Trading Platform)||Yes||Common Shares||DE||EUR||Jun 1996|
|0RLT||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Jun 1996|
|QIAD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Jun 1996|
|QGEN||SWX (SIX Swiss Exchange)||Yes||Common Shares||CH||CHF||Jun 1996|
|QGEN||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Jun 1996|
|QIA||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Jun 1996|
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilizati ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 00:26|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.